Page last updated: 2024-10-22

amiodarone and Facial Hemiatrophy

amiodarone has been researched along with Facial Hemiatrophy in 1 studies

Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.

Facial Hemiatrophy: A syndrome characterized by slowly progressive unilateral atrophy of facial subcutaneous fat, muscle tissue, skin, cartilage, and bone. The condition typically progresses over a period of 2-10 years and then stabilizes.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tritakarn, T1
Teeratchanan, T1

Other Studies

1 other study available for amiodarone and Facial Hemiatrophy

ArticleYear
Acute rhabdomyolysis and cardiac arrest following succinylcholine in a patient with Parry-Romberg syndrome.
    Anaesthesia and intensive care, 2011, Volume: 39, Issue:1

    Topics: Acute Disease; Adolescent; Amiodarone; Anti-Arrhythmia Agents; Calcium Gluconate; Cardiopulmonary Re

2011